Definium Therapeutics (NASDAQ:DFTX) Stock Price Up 7.5% – Time to Buy?

Definium Therapeutics, Inc. (NASDAQ:DFTX) shares traded up 7.5% on Friday. The stock traded as high as $37.11 and last traded at $36.74. Approximately 558,121 shares changed hands during trading, a decline of 75% from the average daily volume of 2,260,108 shares. The stock had previously closed at $34.18.

Wall Street Analyst Weigh In

DFTX has been the topic of several recent research reports. Robert W. Baird upped their price objective on shares of Definium Therapeutics from $75.00 to $79.00 and gave the company an “outperform” rating in a report on Tuesday, September 15th. Citigroup reissued a “buy” rating on shares of Definium Therapeutics in a report on Monday, June 22nd. Leerink Partners set a $52.00 price objective on shares of Definium Therapeutics and gave the company an “outperform” rating in a research note on Monday, June 22nd. Piper Sandler reissued an “overweight” rating and issued a $75.00 price target (up from $73.00) on shares of Definium Therapeutics in a report on Friday, August 7th. Finally, Stifel Nicolaus boosted their target price on Definium Therapeutics from $30.00 to $60.00 and gave the stock a “buy” rating in a research report on Wednesday, July 8th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Buy” and an average target price of $66.00.

Definium Therapeutics Stock Up 8.3%

The company has a market cap of $4.97 billion, a PE ratio of -10.79 and a beta of 2.19. The stock’s 50 day moving average price is $40.43 and its 200-day moving average price is $32.95. The company has a debt-to-equity ratio of 0.04, a quick ratio of 6.95 and a current ratio of 6.95.

Definium Therapeutics (NASDAQ:DFTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.89). On average, analysts predict that Definium Therapeutics, Inc. will post -3.02 earnings per share for the current year.

Insider Activity

In related news, insider Mark Sullivan sold 14,051 shares of the business’s stock in a transaction dated Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $513,845.07. Following the transaction, the insider owned 494,228 shares in the company, valued at $18,073,917.96. The trade was a 2.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Brandi Roberts sold 3,377 shares of the business’s stock in a transaction dated Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $123,496.89. Following the transaction, the chief financial officer owned 394,528 shares in the company, valued at approximately $14,427,888.96. This represents a 0.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 71,098 shares of company stock worth $2,626,115 in the last quarter. Insiders own 2.40% of the company’s stock.

Hedge Funds Weigh In On Definium Therapeutics

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC lifted its stake in Definium Therapeutics by 28.3% in the third quarter. GAMMA Investing LLC now owns 1,555 shares of the company’s stock worth $59,000 after acquiring an additional 343 shares during the period. Farther Finance Advisors LLC boosted its stake in shares of Definium Therapeutics by 961.8% during the 3rd quarter. Farther Finance Advisors LLC now owns 12,338 shares of the company’s stock valued at $470,000 after purchasing an additional 11,176 shares in the last quarter. Sequoia Financial Advisors LLC purchased a new position in shares of Definium Therapeutics during the second quarter valued at about $812,000. WINTON GROUP Ltd purchased a new stake in Definium Therapeutics in the second quarter worth about $240,000. Finally, Engineers Gate Manager LP bought a new stake in Definium Therapeutics during the 2nd quarter valued at approximately $481,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.